Applications of proteomics in oncology

Pharmacogenomics

Volumn 1, Issue 4, 2000, Pages 385-393

  Jain, Kewal K ^a  

^a JAIN PHARMABIOTECH   (Switzerland)

Author keywords

Anticancer drugs; Cancer; Cancer Genome Anatomy Project (CGAP); Genomics; Laser capture microdissection (LCM); Mass spectrometry (MS); Matrix assisted laser desorption ionisation (MALDI); Molecular diagnosis of cancer; Nuclear matrix proteins (NMPs)

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEOME; TUMOR PROTEIN;

ANIMAL; BIOSYNTHESIS; GENETICS; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; PHARMACOGENETICS; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PHARMACOGENETICS; PROTEOME;

EID: 0034331666     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.1.4.385     Document Type: Review

References (30)

1. JAIN KK: Proteomics: technologies and commercial potential. Jain PharmaBiotech Publications, Basel, Switzerland (2000):1-290. A detailed report on proteomic technologies and their applications in basic research, drug discovery, molecular diagnostics and healthcare. Also contains profiles of 130 companies involved in proteomics and an analysis of commercial opportunities.
2. JAIN KK: Molecular diagnostics: technologies and commercial potential. Decision Resources, Inc., Waltham, Massachusetts, USA (1999).
3. SIMPSON RJ, CONNOLLY LM, EDDES JS et al.: Proteomic analysis of the human colon carcinoma cell line (LIM 1215): development of a membrane protein database. Electrophoresis (2000) 21:1707-1732.
4. PALMER-TOY DE, SARRACINO DA, SGROI D, LEVANGIE R, LEOPOLD PE: Direct acquisition of matrix-assisted laser desorption/ionization time-of-flight mass spectra from laser capture microdissected tissues. Clin. Chem. (2000) 46:1513-1516.
5. FEND F, RAFFELD M: Laser capture microdissection in pathology. J. Clin. Pathol. (2000) 53:666-672. An excellent description of the technique of LCM and overview of current applications with perspective on future.
6. SIMONE NL, BONNER RF, GILLESPIE JW et al.: Laser capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genetics (1998) 14:272-276.
7. CELIS JE, KRUHOFFER M, GROMOVA I et al.: Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett. (2000a) 480:2-16.
8. PAWELETZ CP: A novel, proteomic approach to monitor carcinogenic disease progression using surface enhanced desorption ionization spectroscopy (SELDI) of laser capture microdissection (LCM)-derived cells from cancer tissue. Proc. Am. Assoc. Cancer Res. (1999) 40:411.
9. SENIOR K: Fingerprinting disease with protein chip arrays. Mol. Med. Today (1999) 5:326-327.
10. UNWIN RD, KNOWLES MA, SELBY PJ et al.: Urological malignancies and the proteomic-genomic interface. Electrophoresis (1999) 20:3629-3637.
11. SEOW TK, ONG SE, LIANG RC et al.: Two-dimensional electrophoresis map of the human hepatocellular carcinoma cell line, HCC-M and identification of the separated proteins by mass spectrometry. Electrophoresis (2000) 21:1787-813.
12. JUNGBLUT PR, ZIMNY-ARNDT U, ZEINDL-EBERHART E et al.: Proteomics in human disease: cancer, heart and infectious diseases. Electrophoresis (1999) 20:2100-2110.
13. NELSON PS, HAN D, ROCHON Y et al.: Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics. Electrophoresis (2000) 21:1823-1831.
14. SIMONE NL, REMALEY AT, CHARBONEAU L et al.: Sensitive immunoassay of tissue cell proteins procured by laser capture microdissection. Am. J. Pathol. (2000) 156:445-452.
15. ORNSTEIN DK, GILLESPIE JW, PAWELETZ CP et al.: Protcomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis (2000) 21:2235-2242.
16. PAGE MJ, AMESS B, TOWNSEND RR et al.: Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc. Natl. Acad. Sci. USA (1999) 96:12589-12594.
17. EMMERT-BUCK MR, GILLESPIE JW, PAWELETZ CP et al.: An approach to proteomic analysis of human tumors. Mol. Carcinog. (2000) 27:158-165.
18. ORNTOFT TF, WOLF H: Molecular alterations in bladder cancer. Urol. Res. (1998) 26:223-233.
19. ABOAGYE-MATHIESEN G, EBBESEN P, VON DER MAASE H et al.: Interferon gamma regulates a unique set of proteins in fresh human bladder transitional cell carcinomas. Electrophoresis (1999) 20:344-348.
20. NIENABER VL, RICHARDSON PL, KLIGHOFER V et al.: Discovering novel ligands for macromolecules using x-ray crystallographic screening. Nature Biotechnol. (2000) 18:1105-1108.
21. MCKERROW JH, BHARGAVA V, HANSELL E et al.: A functional proteomics screen of proteases in colorectal carcinoma. Mol. Med. (2000) 6:450-460.
22. MCKENZIE E, TYSON K, STAMPS A et al. Cloning and expression profiling of hpa2, a novel mammalian heparanase family member. Biochem. Biophys. Res. Commun. (2000) 276:1170-1177.
23. VLODAVSKY I, MOHSEN M, LIDER O et al.: Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis (1995) 14:290-302.
24. ALAIYA AA, FRANZEN B, AUER G et al.: Cancer proteomics: from identification of novel markers to creation of artificial learning models for tumor classification. Electrophoresis (2000) 21:1210-1217.
25. JOHNSON PJ: Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J. Gastroenterol. Hepatol. (1999) 14(Suppl.):S32-S36.
26. CELIS JE, WOLF H, OSTERGAARD M: Bladder squamous cell carcinoma biomarkers derived from proteomics. Electrophoresis (2000b) 21:2115-2121.
27. BURCHARDT M, BURCHARDT T, SHABSIGH A et al.: Current concepts in biomarker technology for bladder cancers. Clin. Chem. (2000) 46:595-605.
28. SOMOZA JR, ZHAN H, BOWMAN KK et al.: Crystal structure of human cathepsin V. Biochemistry (2000) 39:12543-12551.
29. http://www.ludwig.edu.au/jpsl/jpslhome.html Ludwig Institute For Cancer Research (Melbourne Branch) & The Walter and Eliza Hall Institute Of Medical Research: Membrane protein database. (2000).
30. http://www.nci.nih.gov National Cancer Institute (2000).